Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL)
Summary
Candel Therapeutics, Inc. could surge as aglatimagene nears Phase 3 prostate cancer readouts and a BLA; click to explore CADL stock upside, risks, and more.
Description
Candel Therapeutics, Inc. could surge as aglatimagene nears Phase 3 prostate cancer readouts and a BLA; click to explore CADL stock upside, risks, and more.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source